Napo Pharmaceuticals
Crofelemer
A proprietary gastro-intestinal compound in clinical development for four distinct product indications
people
Board of Directors
Dennis M. Fenton
Non-Executive Director
Dr. Fenton joined the Board of Napo Pharmaceuticals, Inc. in May 2011. Dr. Fenton has over thirty years of pharmaceutical and biotechnology experienceincluding over 25 years at Amgen, Inc. where he coordinated the design, construction and expansion of manufacturing facilities for Epogen(R) (epoetin alfa) and Neupogen(R) (filgrastim), two of the premier products in the biotechnology industry. Dr. Fenton served in numerous positions at Amgen including executive roles in process development, manufacturing, sales and marketing and research and development, with his last position being Executive Vice President
Dr. Fenton is a director of life science companies including Xenoport, Inc., Amira Pharmaceuticals, Inc., Genelux Corporation and Kythera Biopharmaceuticals. He is a Director/Trustee at Rutgers University and a Trustee of the Keck Graduate Institute, and the Biotechnology Institute.
Dr. Fenton holds 5 US patents in microbiology and has published over 50 papers and abstracts. Dr. Fenton has a B.S. in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University.